1. Home
  2. News Archive

More News

CSI Dry Eye Software Appoints Ken Barbet as CEO
CSI Dry Eye Software Appoints Ken Barbet as CEO

CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease diagnosis and management, announced April 23 that it had appointed Ken Barbet as chief executive officer. CSI ...

Aurion Biotech Appoints Edward J. Holland, MD, as Chief Medical Officer
Aurion Biotech Appoints Edward J. Holland, MD, as Chief Medical Officer

Aurion Biotech announced April 23 that it had appointed Edward J. Holland, MD, as chief medical officer. Aurion’s lead asset is AURN001, being developed for corneal edema secondary to corneal endot...

Design Therapeutics Appoints Chris M. Storgard, MD, as Chief Medical Officer
Design Therapeutics Appoints Chris M. Storgard, MD, as Chief Medical Officer

Design Therapeutics announced April 17 that it had appointed Chris M. Storgard, MD, as chief medical officer (CMO). The Carlsbad, California, company is developing DT-168, a small molecule targetin...

Bausch + Lomb Ends Recall of enVista IOLs After Tracking Source of Contamination
Bausch + Lomb Ends Recall of enVista IOLs After Tracking Source of Contamination

Bausch + Lomb announced April 24 that it was ending its voluntary recall of enVista intraocular lenses (IOLs) after it tracked the source of contamination to a raw material used in certain lots tha...

GA Patients in Eyestem Phase I Cell Therapy Trial Show Significant Vision Improvement
GA Patients in Eyestem Phase I Cell Therapy Trial Show Significant Vision Improvement

India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...

Four Eylea Biosimilars Get Q-Codes for Billing Payers in the US
Four Eylea Biosimilars Get Q-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) issued product-specific Q-codes for four Eylea biosimilars during Q4-2024 and Q1-2025. Q-codes are billing codes for reimbursement that are simi...

Alcon Rolls Out Unity VCS and CS Systems at ASCRS Meeting
Alcon Rolls Out Unity VCS and CS Systems at ASCRS Meeting

Alcon announced April 25 the launch of its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) in four markets, including the US. The announcement cam...

Veo Launches Plexitome to Treat Recurrent Corneal Erosion, Corneal Abrasions
Veo Launches Plexitome to Treat Recurrent Corneal Erosion, Corneal Abrasions

Veo Ophthalmics, of Chester, Ohio, announced April 14 that it had launched its Plexitome surgical instrument for the treatment of recurrent corneal erosion and large corneal abrasions. The FDA-regi...

US FDA Rejects Regeneron’s sBLA for Eylea HD Dosing Interval Beyond 16 Weeks
US FDA Rejects Regeneron’s sBLA for Eylea HD Dosing Interval Beyond 16 Weeks

Regeneron announced April 18 that the US FDA had issued a complete response letter rejecting the company’s supplemental biologics license application (sBLA) to add extended dosing intervals up to e...

Ballooning NHS Cataract Surgery Costs at Private Clinics Raise Red Flags
Ballooning NHS Cataract Surgery Costs at Private Clinics Raise Red Flags

Fraud investigators in England’sNational Health Service (NHS) are looking at the billing practices of private clinics delivering NHS cataract surgery after procedure volume and costs have ballooned...

New Mexico Governor Vetoes Bill to Allow ODs to Perform SLT, YAG Capsulotomy
New Mexico Governor Vetoes Bill to Allow ODs to Perform SLT, YAG Capsulotomy

New Mexico Gov. Michelle Lujan Grisham on April 11 vetoed House Bill 36, which would have expanded the scope of practice for optometrists in the state, allowing them to perform selective laser trab...

Microsurgical Technology to Distribute MANI’s Ophthalmic Blade Portfolio in US
Microsurgical Technology to Distribute MANI’s Ophthalmic Blade Portfolio in US

Microsurgical Technology (MST) announced April 17 that, under a new strategic partnership, it would distribute the ophthalmic surgical blade portfolio of Japan’s MANI in the US. The deal is concurr...

Senju Licenses Brill’s Non-contact Esthesiometer for Japan
Senju Licenses Brill’s Non-contact Esthesiometer for Japan

Japanese company Senju Pharmaceutical reported March 7 that it had licensed Brill International’s corneal esthesiometer for use in Japan. Senju said the device mainly had been distributed by Brill ...

May 12 is Deadline to Apply for Ramin Tadayoni Award for Research
May 12 is Deadline to Apply for Ramin Tadayoni Award for Research

Applications are open until May 12, 2025, for this year’s Ramin Tadayoni Award, offered by the European Society of Retina Specialists, or Euretina, and supported by Oculis as a tribute to retina sp...

Combined APAO-AIOS Meeting Draws 12,500 to New Convention Center in India
Combined APAO-AIOS Meeting Draws 12,500 to New Convention Center in India

Around 12,500 delegates attended the 2025 joint meeting of the Asia-Pacific Academy of Ophthalmology and All-India Ophthalmolog-ical Society, with more than 1,300 international visitors. The confer...

Asia-Pacific Leads Push to Get AI from the Bench to the Bedside
Asia-Pacific Leads Push to Get AI from the Bench to the Bedside

Bridging the gap between artificial intelligence development and deployment in ophthalmology was the main theme of a Thursday morning session on AI innovation at the 2025 APAO-AIOS meeting. Paisan ...

Ophthalmic Venture Capital Funding Hits a Seven-Quarter Peak
Ophthalmic Venture Capital Funding Hits a Seven-Quarter Peak

Venture capital investments accounted for over half of all ophthalmic deals in Q1-2025, with financing rounds totaling $515.7 million—the highest quarter since Q3-2023, when these transactions reac...

Better IOLs, Push from Surgeons Will Drive Healthy Premium Growth
Better IOLs, Push from Surgeons Will Drive Healthy Premium Growth

Cataract surgeons’ focus on premium IOLs will increase over the next five years due to improved technology and continued declines in reimbursement for monofocal cataract surgery. Premium IOLs, incl...

Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million
Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million

Alcon announced March 24 that it had entered into a definitive agreement to acquire Lensar, including its Ally femtosecond laser cataract system, its Streamline software, and the Lensar legacy lase...

Alcon Introduces Clareon PanOptix Pro IOL
Alcon Introduces Clareon PanOptix Pro IOL

Alcon on April 2 introduced its Clareon PanOptix Pro trifocal IOL, a next-generation version of its groundbreaking PanOptix model. The company said the lens had been made available to select US pra...

US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for Yet Another Symptom Trial
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for Yet Another Symptom Trial

Aldeyra Therapeutics reported April 3 that the US FDA had once again issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment for d...

Orasis Launches Qlosi Presbyopia Drops in US
Orasis Launches Qlosi Presbyopia Drops in US

Orasis Pharmaceuticals announced April 7 that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% eye drops for the treatment of presbyopia are now available to prescribe in the US. Orasis s...

Select US FDA Approvals and Clearances in March 2025
Select US FDA Approvals and Clearances in March 2025

There was one US FDA clearance through the ophthalmic device division using the 510(k) pathway in March 2025, according to the agency’s database. CenterVue gained approval for its Maia scanning las...

Nordic Pharma Secures CE Marking for Lacrifill Canalicular Gel in Dry Eye
Nordic Pharma Secures CE Marking for Lacrifill Canalicular Gel in Dry Eye

Nordic Group B.V., a Dutch affiliate of Nordic Pharma, announced April 7 that Lacrifill canalicular gel had received CE marking in Europe for the treatment of dry eye. Lacrifill is a cross-linked h...

PDUFA Dates for Ophthalmic Drug Candidates, April 2025
PDUFA Dates for Ophthalmic Drug Candidates, April 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Accepts Outlook’s Resubmitted BLA for Lytenava, Sets PDUFA Date of Aug. 27
US FDA Accepts Outlook’s Resubmitted BLA for Lytenava, Sets PDUFA Date of Aug. 27

Outlook Therapeutics announced April 8 that the US FDA had accepted the resubmitted biologics license application (BLA) for ONS-5010 (bevacizumab-vikg, Lytenava), an ophthalmic formulation of bevac...

Atsena Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Atsena Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Atsena Therapeutics led recent ophthalmic fundraising efforts with $150 million in Series C funding, led by new investor Bain Capital, to advance its gene therapy candidates. Financing announced in...

2025-2026 Ophthalmic Meetings Calendar
2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Delegates Debate Best Options to Combat Asia’s Pediatric Myopia Epidemic
Delegates Debate Best Options to Combat Asia’s Pediatric Myopia Epidemic

The treatment of myopia progression with low-concentration atropine (LCA) drops was the most discussed intervention for the disease among delegates at the 2025 APAO-AIOS meeting. Globally, more tha...

Indian Glaucoma Surgeons Embrace MIGS Procedures Over Devices
Indian Glaucoma Surgeons Embrace MIGS Procedures Over Devices

Most MIGS (minimally invasive glaucoma surgery) sessions at major ophthalmic meetings talk about devices. Indian doctors at the MIGS sessions of the joint APAO-AIOS congress in April mostly talked ...

Malvina Eydelman, MD, Named CEO of CCOI Organization
Malvina Eydelman, MD, Named CEO of CCOI Organization

Longtime US FDA regulator and board-certified ophthalmologist Malvina Eydelman, MD, has stepped into a new role as chief executive officer of the Collaborative Community on Ophthalmic Innovation (C...

Retina Pharma and Premium IOLs Continue to Drive Ophthalmic Market
Retina Pharma and Premium IOLs Continue to Drive Ophthalmic Market

The ophthalmology industry produced an estimated $48.8 billion in revenue in 2024, with an expected compound annual growth rate (CAGR) of 4.5 percent. Market Scope estimates the industry will reach...

Opthea Discontinues Wet AMD Program After Second Phase III Trial Misses Endpoint
Opthea Discontinues Wet AMD Program After Second Phase III Trial Misses Endpoint

Opthea announced March 31 its decision to discontinue development of sozinibercept (OPT-302) in wet age-related macular degeneration (AMD) after a second Phase III trial missed its primary endpoint...

Clinical Trial Updates for Ophthalmic Candidates, April 2025
Clinical Trial Updates for Ophthalmic Candidates, April 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Job and Funding Cuts in US HHS Department Hit Ophthalmic Community
Job and Funding Cuts in US HHS Department Hit Ophthalmic Community

The Trump administration’s overhaul of the US Health and Human Services Department (HHS) through mass firings, funding cuts, and restructuring continues to affect those working to protect vision. J...

Alcon Announces Majority Ownership of Aurion Cell Therapy Company
Alcon Announces Majority Ownership of Aurion Cell Therapy Company

Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...

Bausch + Lomb Recalls Certain enVista IOLs Amid Reports of TASS Cases
Bausch + Lomb Recalls Certain enVista IOLs Amid Reports of TASS Cases

Bausch + Lomb announced March 27 that it was voluntarily recalling certain intraocular lenses (IOLs) on its enVista platform. A letter to customers from Bausch + Lomb Chairman and CEO Brent Saunder...

US FDA Plans to Phase Out Animal Testing for Biologics, Drugs
US FDA Plans to Phase Out Animal Testing for Biologics, Drugs

The US FDA reported April 10 that it planned to phase out animal testing as part of the approval process for biologics and drugs, as the agency moves to more effective, human-relevant methods, call...

Topcon to Go Private Through Tender Offer by KKR and JIC Capital
Topcon to Go Private Through Tender Offer by KKR and JIC Capital

Publicly held Topcon plans to go private under a $2.3 billion tender offer by private equity firm KKR, headquartered in New York, and JIC Capital, the private equity arm of Japan’s government-owned...

Emerging Companies Pursuing Ophthalmic Indications, April 2025
Emerging Companies Pursuing Ophthalmic Indications, April 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Biocon’s Deal with Regeneron Will Bring Yesafili to Market in US No Later than H2-2026
Biocon’s Deal with Regeneron Will Bring Yesafili to Market in US No Later than H2-2026

India’s Biocon Biologics reported April 15 that it had reached a settlement and license agreement with Regeneron that clears the way for Biocon to commercialize Yesafili, a biosimilar to Eylea, in ...

Thomas Panek Becomes President, CEO of Lighthouse Guild
Thomas Panek Becomes President, CEO of Lighthouse Guild

Lighthouse Guild announced March 18 that it had appointed Thomas Panek as its new president and CEO, effective April 1. Panek replaced Calvin Roberts, MD, who had led the nonprofit since April 2020...

Weekly Surgeon Poll, April 2025
Weekly Surgeon Poll, April 2025

April 2025 Ophthalmic News Briefs
April 2025 Ophthalmic News Briefs

Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...

Biocon Reaches Settlement, License Agreement with Regeneron to Bring Yesafili to Market in US
Biocon Reaches Settlement, License Agreement with Regeneron to Bring Yesafili to Market in US

India’s Biocon Biologics reported April 15 that it had reached a settlement and license agreement with Regeneron that clears the way for Biocon to commercialize Yesafili, a biosimilar to Eylea, in ...

US FDA Grants 510(k) Clearance to BVI’s Laser Endoscopy System for Glaucoma
US FDA Grants 510(k) Clearance to BVI’s Laser Endoscopy System for Glaucoma

BVI Medical announced April 17 that it had received US FDA 510(k) clearance for its Leos laser endoscopy system for glaucoma. The company said Leos offers a more intuitive, minimally invasive ab in...

Sanoculis Receives CE Marking for MINT Procedure for Glaucoma
Sanoculis Receives CE Marking for MINT Procedure for Glaucoma

Israel’s Sanoculis announced April 17 that it had received CE marking in the EU for its MINT (minimally invasive nasal trabeculostomy) procedure for adults with glaucoma. MINT features a mechanical...

J&J Vision Reports Q1-2025 Surgical Revenue of $361 Million
J&J Vision Reports Q1-2025 Surgical Revenue of $361 Million

J&J Vision’s Q1-2025 global surgical revenue totaled $361 million, a 3.7 percent increase (+6.2 percent cc) over $348 million in Q1-2024, parent Johnson & Johnson, of New Brunswick, New Jersey, rep...

Cambridge Innovation Institute Absorbs Healthegy’s OIS, OIS Retina Conferences
Cambridge Innovation Institute Absorbs Healthegy’s OIS, OIS Retina Conferences

Cambridge Innovation Institute, of Needham, Massachusetts, announced April 10 that it would expand its health care event calendar by taking on Healthegy’s ophthalmic conferences—the Ophthalmology I...

US FDA Plans to Phase Out Animal Testing for Biologics, Drugs
US FDA Plans to Phase Out Animal Testing for Biologics, Drugs

The US FDA reported April 10 that it planned to phase out animal testing as part of the approval process for biologics and drugs, as the agency moves to more effective, human-relevant methods, call...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more